APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nonerosive Reflux Disease Treatment

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Nonerosive Reflux Disease Treatment Market Outlook and Growth Opportunities 2026

19 December 2025194 pages

Choose your research edition.

Industry ResearchNonerosive Reflux Disease Treatment Industry Research Report 2026112 pages · $2,950 USDIndustry Growth & TrendsGlobal Nonerosive Reflux Disease Treatment Industry Growth and Trends Forecast to 203288 pages · $3,450 USDMarket StructureGlobal Nonerosive Reflux Disease Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nonerosive Reflux Disease Treatment Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Nonerosive Reflux Disease Treatment Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Nonerosive Reflux Disease Treatment market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Nonerosive Reflux Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Nonerosive Reflux Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Nonerosive Reflux Disease Treatment is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Nonerosive Reflux Disease Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Nonerosive Reflux Disease Treatment market include Takeda Pharmaceutical, Eisai, Johnson & Johnson, GlaxoSmithKline, AstraZeneca, SRS Pharmaceuticals, SFJ Pharmaceuticals Group, Ironwood Pharmaceuticals and Daewoong Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Nonerosive Reflux Disease Treatment market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Nonerosive Reflux Disease Treatment and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Nonerosive Reflux Disease Treatment revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Nonerosive Reflux Disease Treatment market.

Nonerosive Reflux Disease Treatment Segment by Company

Takeda Pharmaceutical

Eisai

Johnson & Johnson

GlaxoSmithKline

AstraZeneca

SRS Pharmaceuticals

SFJ Pharmaceuticals Group

Ironwood Pharmaceuticals

Daewoong Pharmaceutical

Nonerosive Reflux Disease Treatment Segment by Type

H2 Receptor Antagonists

Antacids

Proton pump inhibitors

Others

Nonerosive Reflux Disease Treatment Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Nonerosive Reflux Disease Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Nonerosive Reflux Disease Treatment status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Nonerosive Reflux Disease Treatment key companies, revenue, market share, and recent developments.

3. To split the Nonerosive Reflux Disease Treatment breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Nonerosive Reflux Disease Treatment market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Nonerosive Reflux Disease Treatment significant trends, drivers, influence factors in global and regions.

6. To analyze Nonerosive Reflux Disease Treatment competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nonerosive Reflux Disease Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nonerosive Reflux Disease Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nonerosive Reflux Disease Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Nonerosive Reflux Disease Treatment industry.

Chapter 3: Detailed analysis of Nonerosive Reflux Disease Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Nonerosive Reflux Disease Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Nonerosive Reflux Disease Treatment in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Nonerosive Reflux Disease Treatment Industry Trends Table 2. Nonerosive Reflux Disease Treatment Industry Drivers Table 3. Nonerosive Reflux Disease Treatment Industry Opportunities and Challenges Table 4. Nonerosive Reflux Disease Treatment Industry Restraints Table 5. Global Nonerosive Reflux Disease Treatment Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Nonerosive Reflux Disease Treatment Revenue Share by Company (2021-2026) Table 7. Global Nonerosive Reflux Disease Treatment Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Nonerosive Reflux Disease Treatment Key Company Manufacturing Base & Headquarters Table 9. Global Nonerosive Reflux Disease Treatment Company, Product Type & Application Table 10. Global Nonerosive Reflux Disease Treatment Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Nonerosive Reflux Disease Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of H2 Receptor Antagonists Table 15. Significant Companies of Antacids Table 16. Significant Companies of Proton pump inhibitors Table 17. Significant Companies of Others Table 18. Global Nonerosive Reflux Disease Treatment Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Nonerosive Reflux Disease Treatment Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Nonerosive Reflux Disease Treatment Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Nonerosive Reflux Disease Treatment Sales Value Share by Type (2021-2026) Table 22. Global Nonerosive Reflux Disease Treatment Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Pharmacies Table 24. Significant Companies of Online Pharmacies Table 25. Significant Companies of Retail Pharmacies Table 26. Global Nonerosive Reflux Disease Treatment Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Nonerosive Reflux Disease Treatment Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Nonerosive Reflux Disease Treatment Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Nonerosive Reflux Disease Treatment Sales Value Share by Application (2021-2026) Table 30. Global Nonerosive Reflux Disease Treatment Sales Value Share by Application (2027-2032) Table 31. Global Nonerosive Reflux Disease Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Nonerosive Reflux Disease Treatment Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Nonerosive Reflux Disease Treatment Sales Value Share by Region (2021-2026) Table 34. Global Nonerosive Reflux Disease Treatment Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Nonerosive Reflux Disease Treatment Sales Value Share by Region (2027-2032) Table 36. Global Nonerosive Reflux Disease Treatment Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Nonerosive Reflux Disease Treatment Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Nonerosive Reflux Disease Treatment Sales Value Market Share by Country (2021-2026) Table 39. Global Nonerosive Reflux Disease Treatment Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Nonerosive Reflux Disease Treatment Sales Value Market Share by Country (2027-2032) Table 41. Takeda Pharmaceutical Company Information Table 42. Takeda Pharmaceutical Business Overview Table 43. Takeda Pharmaceutical Nonerosive Reflux Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Takeda Pharmaceutical Nonerosive Reflux Disease Treatment Product Portfolio Table 45. Takeda Pharmaceutical Recent Development Table 46. Eisai Company Information Table 47. Eisai Business Overview Table 48. Eisai Nonerosive Reflux Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Eisai Nonerosive Reflux Disease Treatment Product Portfolio Table 50. Eisai Recent Development Table 51. Johnson & Johnson Company Information Table 52. Johnson & Johnson Business Overview Table 53. Johnson & Johnson Nonerosive Reflux Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Johnson & Johnson Nonerosive Reflux Disease Treatment Product Portfolio Table 55. Johnson & Johnson Recent Development Table 56. GlaxoSmithKline Company Information Table 57. GlaxoSmithKline Business Overview Table 58. GlaxoSmithKline Nonerosive Reflux Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. GlaxoSmithKline Nonerosive Reflux Disease Treatment Product Portfolio Table 60. GlaxoSmithKline Recent Development Table 61. AstraZeneca Company Information Table 62. AstraZeneca Business Overview Table 63. AstraZeneca Nonerosive Reflux Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. AstraZeneca Nonerosive Reflux Disease Treatment Product Portfolio Table 65. AstraZeneca Recent Development Table 66. SRS Pharmaceuticals Company Information Table 67. SRS Pharmaceuticals Business Overview Table 68. SRS Pharmaceuticals Nonerosive Reflux Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. SRS Pharmaceuticals Nonerosive Reflux Disease Treatment Product Portfolio Table 70. SRS Pharmaceuticals Recent Development Table 71. SFJ Pharmaceuticals Group Company Information Table 72. SFJ Pharmaceuticals Group Business Overview Table 73. SFJ Pharmaceuticals Group Nonerosive Reflux Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. SFJ Pharmaceuticals Group Nonerosive Reflux Disease Treatment Product Portfolio Table 75. SFJ Pharmaceuticals Group Recent Development Table 76. Ironwood Pharmaceuticals Company Information Table 77. Ironwood Pharmaceuticals Business Overview Table 78. Ironwood Pharmaceuticals Nonerosive Reflux Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Ironwood Pharmaceuticals Nonerosive Reflux Disease Treatment Product Portfolio Table 80. Ironwood Pharmaceuticals Recent Development Table 81. Daewoong Pharmaceutical Company Information Table 82. Daewoong Pharmaceutical Business Overview Table 83. Daewoong Pharmaceutical Nonerosive Reflux Disease Treatment Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Daewoong Pharmaceutical Nonerosive Reflux Disease Treatment Product Portfolio Table 85. Daewoong Pharmaceutical Recent Development Table 86. Research Programs/Design for This Report Table 87. Authors List of This Report Table 88. Secondary Sources Table 89. Primary Sources List of Figures Figure 1. Nonerosive Reflux Disease Treatment Product Image Figure 2. Global Nonerosive Reflux Disease Treatment Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nonerosive Reflux Disease Treatment Market Size (2021-2032) & (US$ Million) Figure 4. Global Nonerosive Reflux Disease Treatment Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. H2 Receptor Antagonists Image Figure 8. Antacids Image Figure 9. Proton pump inhibitors Image Figure 10. Others Image Figure 11. Global Nonerosive Reflux Disease Treatment Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Nonerosive Reflux Disease Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Nonerosive Reflux Disease Treatment Sales Value Share by Type (2021-2032) Figure 14. Hospital Pharmacies Image Figure 15. Online Pharmacies Image Figure 16. Retail Pharmacies Image Figure 17. Global Nonerosive Reflux Disease Treatment Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Nonerosive Reflux Disease Treatment Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Nonerosive Reflux Disease Treatment Sales Value Share by Application (2021-2032) Figure 20. Global Nonerosive Reflux Disease Treatment Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Nonerosive Reflux Disease Treatment Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Nonerosive Reflux Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 23. North America Nonerosive Reflux Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Nonerosive Reflux Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Nonerosive Reflux Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Nonerosive Reflux Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Nonerosive Reflux Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Nonerosive Reflux Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 29. South America Nonerosive Reflux Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Nonerosive Reflux Disease Treatment Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Nonerosive Reflux Disease Treatment Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • H2 Receptor Antagonists
  • Antacids
  • Proton pump inhibitors
  • Others
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Takeda Pharmaceutical
  • Eisai
  • Johnson & Johnson
  • GlaxoSmithKline
  • AstraZeneca
  • SRS Pharmaceuticals
  • SFJ Pharmaceuticals Group
  • Ironwood Pharmaceuticals
  • Daewoong Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Nonerosive Reflux Disease Treatment Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Nonerosive Reflux Disease Treatment Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Nonerosive Reflux Disease Treatment Market Dynamics
  1. 2.1 Nonerosive Reflux Disease Treatment Industry Trends
  2. 2.2 Nonerosive Reflux Disease Treatment Industry Drivers
  3. 2.3 Nonerosive Reflux Disease Treatment Industry Opportunities and Challenges
  4. 2.4 Nonerosive Reflux Disease Treatment Industry Restraints
3 Nonerosive Reflux Disease Treatment Market by Company
  1. 3.1 Global Nonerosive Reflux Disease Treatment Company Revenue Ranking in 2025
  2. 3.2 Global Nonerosive Reflux Disease Treatment Revenue by Company (2021-2026)
  3. 3.3 Global Nonerosive Reflux Disease Treatment Company Ranking (2024-2026)
  4. 3.4 Global Nonerosive Reflux Disease Treatment Company Manufacturing Base and Headquarters
  5. 3.5 Global Nonerosive Reflux Disease Treatment Company Product Type and Application
  6. 3.6 Global Nonerosive Reflux Disease Treatment Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Nonerosive Reflux Disease Treatment Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Nonerosive Reflux Disease Treatment Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Nonerosive Reflux Disease Treatment Market by Type
  1. 4.1 Nonerosive Reflux Disease Treatment Type Introduction
  2. 4.1.1 H2 Receptor Antagonists
  3. 4.1.2 Antacids
  4. 4.1.3 Proton pump inhibitors
  5. 4.1.4 Others
  6. 4.2 Global Nonerosive Reflux Disease Treatment Sales Value by Type
  7. 4.2.1 Global Nonerosive Reflux Disease Treatment Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Nonerosive Reflux Disease Treatment Sales Value by Type (2021-2032)
  9. 4.2.3 Global Nonerosive Reflux Disease Treatment Sales Value Share by Type (2021-2032)
5 Nonerosive Reflux Disease Treatment Market by Application
  1. 5.1 Nonerosive Reflux Disease Treatment Application Introduction
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Nonerosive Reflux Disease Treatment Sales Value by Application
  6. 5.2.1 Global Nonerosive Reflux Disease Treatment Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Nonerosive Reflux Disease Treatment Sales Value by Application (2021-2032)
  8. 5.2.3 Global Nonerosive Reflux Disease Treatment Sales Value Share by Application (2021-2032)
6 Nonerosive Reflux Disease Treatment Regional Value Analysis
  1. 6.1 Global Nonerosive Reflux Disease Treatment Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Nonerosive Reflux Disease Treatment Sales Value by Region (2021-2032)
  3. 6.2.1 Global Nonerosive Reflux Disease Treatment Sales Value by Region: 2021-2026
  4. 6.2.2 Global Nonerosive Reflux Disease Treatment Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Nonerosive Reflux Disease Treatment Sales Value (2021-2032)
  7. 6.3.2 North America Nonerosive Reflux Disease Treatment Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Nonerosive Reflux Disease Treatment Sales Value (2021-2032)
  10. 6.4.2 Europe Nonerosive Reflux Disease Treatment Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Nonerosive Reflux Disease Treatment Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Nonerosive Reflux Disease Treatment Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Nonerosive Reflux Disease Treatment Sales Value (2021-2032)
  16. 6.6.2 South America Nonerosive Reflux Disease Treatment Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Nonerosive Reflux Disease Treatment Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Nonerosive Reflux Disease Treatment Sales Value Share by Country, 2025 VS 2032
7 Nonerosive Reflux Disease Treatment Country-level Value Analysis
  1. 7.1 Global Nonerosive Reflux Disease Treatment Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Nonerosive Reflux Disease Treatment Sales Value by Country (2021-2032)
  3. 7.2.1 Global Nonerosive Reflux Disease Treatment Sales Value by Country (2021-2026)
  4. 7.2.2 Global Nonerosive Reflux Disease Treatment Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Nonerosive Reflux Disease Treatment Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Nonerosive Reflux Disease Treatment Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Nonerosive Reflux Disease Treatment Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical
  2. 8.1.1 Takeda Pharmaceutical Company Information
  3. 8.1.2 Takeda Pharmaceutical Business Overview
  4. 8.1.3 Takeda Pharmaceutical Nonerosive Reflux Disease Treatment Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Nonerosive Reflux Disease Treatment Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Recent Developments
  7. 8.2 Eisai
  8. 8.2.1 Eisai Company Information
  9. 8.2.2 Eisai Business Overview
  10. 8.2.3 Eisai Nonerosive Reflux Disease Treatment Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eisai Nonerosive Reflux Disease Treatment Product Portfolio
  12. 8.2.5 Eisai Recent Developments
  13. 8.3 Johnson & Johnson
  14. 8.3.1 Johnson & Johnson Company Information
  15. 8.3.2 Johnson & Johnson Business Overview
  16. 8.3.3 Johnson & Johnson Nonerosive Reflux Disease Treatment Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Johnson & Johnson Nonerosive Reflux Disease Treatment Product Portfolio
  18. 8.3.5 Johnson & Johnson Recent Developments
  19. 8.4 GlaxoSmithKline
  20. 8.4.1 GlaxoSmithKline Company Information
  21. 8.4.2 GlaxoSmithKline Business Overview
  22. 8.4.3 GlaxoSmithKline Nonerosive Reflux Disease Treatment Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline Nonerosive Reflux Disease Treatment Product Portfolio
  24. 8.4.5 GlaxoSmithKline Recent Developments
  25. 8.5 AstraZeneca
  26. 8.5.1 AstraZeneca Company Information
  27. 8.5.2 AstraZeneca Business Overview
  28. 8.5.3 AstraZeneca Nonerosive Reflux Disease Treatment Revenue and Gross Margin (2021-2026)
  29. 8.5.4 AstraZeneca Nonerosive Reflux Disease Treatment Product Portfolio
  30. 8.5.5 AstraZeneca Recent Developments
  31. 8.6 SRS Pharmaceuticals
  32. 8.6.1 SRS Pharmaceuticals Company Information
  33. 8.6.2 SRS Pharmaceuticals Business Overview
  34. 8.6.3 SRS Pharmaceuticals Nonerosive Reflux Disease Treatment Revenue and Gross Margin (2021-2026)
  35. 8.6.4 SRS Pharmaceuticals Nonerosive Reflux Disease Treatment Product Portfolio
  36. 8.6.5 SRS Pharmaceuticals Recent Developments
  37. 8.7 SFJ Pharmaceuticals Group
  38. 8.7.1 SFJ Pharmaceuticals Group Company Information
  39. 8.7.2 SFJ Pharmaceuticals Group Business Overview
  40. 8.7.3 SFJ Pharmaceuticals Group Nonerosive Reflux Disease Treatment Revenue and Gross Margin (2021-2026)
  41. 8.7.4 SFJ Pharmaceuticals Group Nonerosive Reflux Disease Treatment Product Portfolio
  42. 8.7.5 SFJ Pharmaceuticals Group Recent Developments
  43. 8.8 Ironwood Pharmaceuticals
  44. 8.8.1 Ironwood Pharmaceuticals Company Information
  45. 8.8.2 Ironwood Pharmaceuticals Business Overview
  46. 8.8.3 Ironwood Pharmaceuticals Nonerosive Reflux Disease Treatment Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Ironwood Pharmaceuticals Nonerosive Reflux Disease Treatment Product Portfolio
  48. 8.8.5 Ironwood Pharmaceuticals Recent Developments
  49. 8.9 Daewoong Pharmaceutical
  50. 8.9.1 Daewoong Pharmaceutical Company Information
  51. 8.9.2 Daewoong Pharmaceutical Business Overview
  52. 8.9.3 Daewoong Pharmaceutical Nonerosive Reflux Disease Treatment Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Daewoong Pharmaceutical Nonerosive Reflux Disease Treatment Product Portfolio
  54. 8.9.5 Daewoong Pharmaceutical Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst